We can do better - Improving outcomes in the midst of an emergency

New England Journal of Medicine

Volumn 377, Issue 15, 2017, Pages 1482-1484

  Baden, Lindsey R ^a   Rubin, Eric J ^a   Morrissey, Stephen ^a   Farrar, Jeremy J ^a   Drazen, Jeffrey M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; FAVIPIRAVIR;

ANTIVIRAL THERAPY; CASE FATALITY RATE; EBOLA HEMORRHAGIC FEVER; EDITORIAL; EMERGENCY; EPIDEMIC; GUINEA; HUMAN; INFECTION CONTROL; LIBERIA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEMINAL PLASMA; SIERRA LEONE; VIRUS; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; HOSPITAL EMERGENCY SERVICE;

EMERGENCY SERVICE, HOSPITAL; HUMANS;

EID: 85030976542     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1712330     Document Type: Editorial

References (14)

1. Deen GF, Broutet N, Xu W, et al. Ebola RNA persistence in semen of Ebola virus disease survivors — final report. N Engl J Med 2017;377:1428-37.
2. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014;371:2092-100.
3. Ansumana R, Jacobsen KH, Sahr F, et al. Ebola in Freetown area, Sierra Leone — a case study of 581 patients. N Engl J Med 2015;372:587-8.
4. Cox E, Borio L, Temple R. Evaluating Ebola therapies — the case for RCTs. N Engl J Med 2014;371:2350-1.
5. Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014;371:2394-401.
6. Dunning J, Sahr F, Rojek A, et al. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med 2016;13(4):e1001997.
7. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 2016;13(3):e1001967.
8. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016;374:33-42.
9. Gignoux E, Azman AS, de Smet M, et al. Effect of artesunate–amodiaquine on mortality related to Ebola virus disease. N Engl J Med 2016;374:23-32.
10. van Griensven J, Edwards T, Baize S. Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies. N Engl J Med 2016;375:2307-9.
11. The PREVAIL II Writing Group, for the Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 2016;375:1448-56.
12. Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 2017;377:1438-47.
13. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 2017;389: 505-18.
14. WHO Ebola Response Team. After Ebola in West Africa — unpredictable risks, preventable epidemics. N Engl J Med 2016; 375:587-96.